For laboratory research use only — not for human or veterinary use. Not evaluated by the U.S. FDA.
Metabolic Peptide
GLP-2 (T)
A dual GIP and GLP-1 receptor agonist, studied in clinical research for metabolic regulation and body composition through combined incretin signaling.
Size
Quantity
$88.99
Bundle & save
Delivery
Order by 3:00 PM ET for same-day dispatch
Cutoff 3:00 PM ET · same-day dispatch
Estimated arrival in 2–3 business days
Overnight shipping available
Free shipment protection included
GLP-2 (T)
1 × 10mg · $88.99
99% purity, QC passed
HPLC + mass-spec verified
Shipment protection
Free on every order
Free shipping over $150
Same-day dispatch before 3PM ET
Certificate of Analysis
Third-party tested · Independent analytical lab
10mg
99.71%latest
| Tested | Measured | Purity |
|---|---|---|
| Jun 2026SterileEndotoxin | 12.35mg | 99.71% |
| May 2026 | 12.03mg | 99.53% |
| May 2026 | 11.84mg | 99.68% |
| Apr 2026 | 12.13mg | 99.76% |
| Apr 2026 | 11.88mg | 99.81% |
| Feb 2026 | 12.08mg | 99.69% |
| Dec 2025 | 12.03mg | 99.86% |
| Dec 2025 | 11.58mg | 99.67% |
| Nov 2025 | 11.57mg | 99.71% |
| Nov 2025 | 11.93mg | 99.64% |
Latest safety testing
- Sterility
- TAMC/TYMCJun 2026
- Endotoxin
- <1 EU/vialJun 2026
15mg
99.84%latest
| Tested | Measured | Purity |
|---|---|---|
| Jul 2026 | 17.82mg | 99.84% |
| Apr 2026 | 17.78mg | 99.91% |
| Feb 2026 | 18.80mg | 99.80% |
| Dec 2025 | 16.06mg | 99.89% |
| Nov 2025 | 17.40mg | 99.81% |
| Oct 2025 | 16.96mg | 99.90% |
30mg
99.92%latest
| Tested | Measured | Purity |
|---|---|---|
| Jul 2026MetalsEndotoxin | 37.99mg | 99.92% |
| Jul 2026 | 36.39mg | 99.83% |
| Jun 2026 | 35.49mg | 99.85% |
| Jun 2026 | 33.63mg | 99.76% |
| Jun 2026 | 36.32mg | 99.86% |
| May 2026 | 33.76mg | 99.88% |
| May 2026 | 33.98mg | 99.80% |
| May 2026 | 31.98mg | 99.84% |
| May 2026 | 33.94mg | 99.66% |
| Apr 2026 | 33.94mg | 99.89% |
Latest safety testing
- Heavy metals
- As/Cd/Pb not detectedJul 2026
- Endotoxin
- 1.286 EU/vialJul 2026
60mg
99.87%latest
| Tested | Measured | Purity |
|---|---|---|
| Jul 2026 | 67.71mg | 99.87% |
| Jun 2026 | 67.59mg | 99.77% |
| Jun 2026 | 69.88mg | 99.81% |
| May 2026 | 67.02mg | 99.86% |
| Apr 2026 | 67.16mg | 99.92% |
| Apr 2026 | 67.87mg | 99.91% |
| Mar 2026 | 69.68mg | 99.89% |
| Feb 2026 | 68.10mg | 99.86% |
| Feb 2026 | 67.83mg | 99.92% |
| Jan 2026 | 73.98mg | 99.90% |
100mg
99.91%latest
| Tested | Measured | Purity |
|---|---|---|
| Jul 2026 | 118.53mg | 99.91% |
| Apr 2026 | 113.12mg | 99.92% |
| Feb 2026 | 109.35mg | 99.91% |
| Jan 2026 | 113.02mg | 99.89% |
Endotoxin, sterility, and heavy-metals reports are run on individual lots on a rotating basis, separate from the identity/purity assay above — not on every lot.
Frequently researched together
Commonly studied alongside GLP-2 (T).
Compound information
Technical specifications
Molecular profile
| Type | Dual GIP / GLP-1 receptor agonist |
| CAS number | 2023788-19-2 |
| Molecular weight | 4813 g/mol |
| Amino acids | 39 |
| Formula | C225H348N48O68 |
Storage & stability
- ❄️
Lyophilized (powder)
-20°C · stable 2+ years
- ❄️
Reconstituted
2–8°C · use within 30 days
Sources & references
Peer-reviewed literature, for research context
- The New England journal of medicine
GLP-2 (T) as Compared with GLP-1 (S) for the Treatment of Obesity
2025·DOI: 10.1056/NEJMoa2416394·PMID: 40353578Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E
View source - Lancet (London, England)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist GLP-2 (T) in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
2021·DOI: 10.1016/S0140-6736(21)01324-6·PMID: 34186022Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L
View source - Lancet (London, England)
GLP-2 (T) once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
2023·DOI: 10.1016/S0140-6736(23)01200-X·PMID: 37385275Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D
View source - The New England journal of medicine
GLP-2 (T) for Obesity Treatment and Diabetes Prevention
2025·DOI: 10.1056/NEJMoa2410819·PMID: 39536238Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S
View source
Important research notice
Not for human consumption. This product is sold exclusively for laboratory and in vitro research. It is not intended to diagnose, treat, cure, or prevent any disease.
Any research findings referenced on this page are drawn from published, peer-reviewed literature and are provided for educational context only. They are not product claims and should not be read as medical advice.
By purchasing, you confirm you are a qualified researcher and will handle this material in accordance with all applicable laws and institutional guidelines.